Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience

AIDS Research and Human Retroviruses

Volumn 34, Issue 7, 2018, Pages 570-574

  De Francesco, Maria Antonia ^a   Izzo, Ilaria ^a   Properzi, Martina ^a   Gargiulo, Franco ^a   Caccuri, Francesca ^a   Quiros Roldan, Eugenia ^a   Castelli, Francesco ^a   Caruso, Arnaldo ^a   Focà, Emanuele ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

genotypic test; integrase inhibitors resistance; resistance mutations

Indexed keywords

ANTIRETROVIRUS AGENT; DOLUTEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANTIVIRAL RESISTANCE; ENZYMOLOGY; GENE FREQUENCY; GENETICS; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; ITALY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MISSENSE MUTATION; VIROLOGY;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 85049395343     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2018.0006     Document Type: Article

References (20)

1. Gutierrez C, Hernandez-Novoa B, Perez-Elias MJ, et al. : Prevalence of primary resistance mutations to integrase inhibitors in treatment-nave and-experienced patients in-fected with B and non-B HIV-1 variants. HIV Clin Trials 2013;14:10-16.
2. Wohl DA, Cohen C, Gallant JE, et al. : A randomized, double-blind comparison of single-tablet regimen elvite-gravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65:e118-e120.
3. Goethals O, Clayton R, Van Ginderen M, et al. : Resistance mutations in human immunodeficiency virus type 1 in-tegrase selected with elvitegravir confer reduced suscepti-bility to a wide range of integrase inhibitors. J Virol 2008; 82:10366-10374.
4. Malet I, Delelis O, Valantin MA, et al. : Mutations associ-ated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52:1351-1358.
5. Casadella M, van Ham PM, Noguera-Julian M, et al. : Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother 2015;70:2885-2888.
6. Young B, Fransen S, Greenberg KS, et al. : Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011;16:253-256.
7. Boyd SD, Maldarelli F, Sereti I, et al. : Transmitted ralte-gravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther 2011;16:257-261
8. Rhee SY, Liu TF, Kiuchi M, et al. : Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology 2008;5:74.
9. Liu TF, Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006;42:1608-1618.
10. Bennett DE, Camacho RJ, Otelea D, et al. : Drug resistance mutations for surveillance of transmitted HIV-1 drug-re-sistance: 2009 update. PLoS One 2009;4:e4724.
11. Wensing AM, Calvez V, Gunthard HF, et al. : Update of the drug resistance mutations in HIV-1. Top Antivir Med 2015; 23:132-141.
12. Tostevin A, White E, Dunn D, et al. : Recent trends and patterns in HIV-1 trasmitted drug resistance in the United Kingdom. HIV Med 2016;1:12414.
13. Parczewski M, Leszcz-Pynka M, Urbanska A: Differences in the integrase and reverse transcriptase transmitted re-sistance patterns in Northern Poland. Infect Gen Evol 2017; 49:122-129.
14. Menza TW, Billock R, Samoff E, Eron JJ, Dennis AM: Pre-treatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016. AIDS 2017;31:2235-2244.
15. Lepik KJ, Harrigan PR, Yip B, et al. : Emergent drug re-sistance with integrase stand transfer inhibitor-based regi-mens. AIDS 2017;31:1425-1434.
16. Scherrer AU, Yang WL, Kouyos RD, et al. : Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study. J Infect Dis 2016;214:399-402.
17. Zoufaly A, Kraft C, Schmidbauer C, Puchhammer-Stoeckl E: Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013. Infection 2017;45:165-170.
18. Fourati S, Charpentier C, Amiel C, et al. : Cross-resistance to elvitagravir and dolutegravir in 502 patients failing on raltegravir: A French national study of raltegravir-experienced HIV-1 infected patients. J Antimicrob Che-mother 2015;70:1507-1512.
19. Doyle T, Dunn DT, Ceccherini-Silberstein F, et al. : In-tegrase inhibitor (INI) genotypic resistance in treatment-nave and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother 2015;70: 3080-3086.
20. Ceccherini-Silberstein F, Malet I, Fabeni L, et al. : Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1 infected pa-tients, all nave to integrase inhibitors. J Antimicrob Che-mother 2010;65:2305-2318.